Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK EML4-ALK T1151INST
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Ba/F3 cells expressing EML4-ALK with 1151 Tins treated with alectinib had an IC50 of 165.7 nM, 16x higher than those expressing EML4-ALK wildtype variant 1. EML4-ALK variant 1 expressing H3122 NSCLC cell line was cultured in increasing levels of crizotinib to produce crizotinib resistant cell lines CR1, CR2 and CR3. H3122 CR2 was found to contain an 1151 insT ALK mutation and increased EML4-ALK levels. The H3122 CR2 cell line survival IC50 value for alectinib treatment was approximately 20x higher than that for H3122 cells.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1347
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/173
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Alectinib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 22277784
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Alectinib | Resitance or Non-Reponse | true |